Reference is made to the annual general meeting inNordic Nanovector ASA on28 June 2023 and the approval of a transaction wherebyNordic Nanovector will acquire all outstanding shares in Thor Medical AS against issuance of new shares inNordic Nanovector . Scatec Innovation AS has, together with its subsidiaries Scatec Invest IV AS and Scatec Invest II AS, previously agreed to sell its shares in Thor Medical against receiving 61,901,306 shares inNordic Nanovector subject to the approval of the transaction by the annual general meeting. Pursuant to the agreement, Scatec Innovation, on a consolidated basis, will upon subscription and delivery of shares as resolved by the general meeting ofNordic Nanovector own a total of 61,901,306 shares inNordic Nanovector , corresponding to approximately 26.51% of the share capital and votes in the Company. Scatec Innovation AS will own 57,151,062 shares directly, while Scatec Invest IV AS will own 3,165,920 shares and Scatec Invest II AS will own 1,584,324 shares. Scatec Invest IV AS and Scatec Invest II AS are both wholly owned subsidiaries of Scatec Innovation AS. The ownership has been calculated on the assumption that a share capital increase ofNOK 146,841 related to board compensation and the share capital increase ofNOK 23,353,900.60 related to the acquisition of Thor Medical is completed, resulting in a share capital inNordic Nanovector ofNOK 46,707,801.20 divided on 233,539,006 shares. This disclosure is made pursuant to section 4-2 of theNorwegian Securities Trading Act.
Click here for more information
© Oslo Bors ASA, source